

**AMENDMENTS TO THE DRAWINGS**

A replacement formal drawing for Figure 6 is attached herewith. Please replace Figure 6 (sheet 6) of record with this attached replacement Figure 6.

**REMARKS**

Favorable reconsideration is respectfully requested in view of the foregoing amendments and the following remarks.

**I. CLAIM STATUS AND AMENDMENTS**

Claims 1-19 have been canceled without prejudice or disclaimer thereto. Applicants reserve the right to file a continuation or divisional application on any canceled subject matter.

Claim 20 is newly added. Support for this claim can be found in claims 2, 3 and 6 as filed and on pages 12-15 of the specification as filed. Applicants respectfully request the Examiner to examine this new claim.

Attached herewith is a revised Figure 6 with the lanes identified. Amendments directing its entry into the specification are also incorporated herein.

No new matter has been added.

**II. REJECTIONS**

Applicants note that all formerly pending claims have been canceled and therefore the current rejections are moot.

Applicants further note that Figure 6 has been amended to identify the gel lanes. Applicants further note that the description of the figures on pages 7-9 of the specification sufficiently describe the essential information necessary to understand these figures. Applicants do not believe that USPTO practice requires them to amend these figures to specifically describe this information sufficiently set forth in the legends for the figures. In particular, Applicants note that MPEP § 608.02(V)(n) indicates that symbols may be used to describe portions of figures, if such symbols are described in the specification. Applicants note that a similar situation is presented in this case; the figures use numbers which correspond to the figure legends on pages 7-9 to describe concentrations and other variables. Applicants further note that in regard to Figure 5, letter a-f on page 8, lines 14-15, corresponds to a-f given in the Figure. Thus, Applicants submit that this objection is untenable and should be withdrawn.

Applicants further note that in regard to Karlsson et al. (U.S. Patent 4,859,769), this reference does not teach the use of a molecule of formula (II) for inhibiting a dengue virus infection.

Further, in regard to the enablement rejection, Applicants note that new claim 20 is directed toward a method for inhibiting a dengue virus infection comprising administering an inhibitor containing a molecule with a defined oligosaccharide chain and an "R" group that is a lipid. Applicants note that the scope of the inhibitor in this claim is significantly smaller than the scope of the inhibitor in formerly rejected claims 1, 2 and 6. Applicants further note that the experimental examples in the specification are directed towards an oligosaccharide chain such as the one given in formula (Ia) in claim 20 with an "R" group that is a lipid. For instance, please see page 23 of the specification as filed. Applicants therefore respectfully submit that new claim 20 is enabled for the full scope of *in vivo* inhibition of dengue virus infection.

### III. CONCLUSION


In view of the foregoing amendments and remarks, the present application is in condition for allowance and early notice to that effect is hereby requested.

If the Examiner has any comments or proposals for expediting prosecution, please contact the undersigned attorney at the telephone number below.

Respectfully submitted,

Yasuo SUZUKI et al.

By:

  
\_\_\_\_\_  
William R. Schmidt, II  
Registration No. 58,327  
Attorney for Applicants

WRS/lq  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
April 23, 2008

**ATTACHMENTS**

1. Replacement formal drawing of Figure 6.